Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Re: price drop...........many have high short term expectations...when the pps didn't jump on a few pr's after having drifted downward for awhile, a few jumped...others dumped and the rest was dominoes imho....a self fulfilling prophecy of sorts....if the price reacts back up within a week...this is a sign of good news on the horizon. Others maybe waiting for a retest of the low 30's upper 20's and haven't bought back yet since .80+ and are excited right now. Longs are frustrated and some jump ship or sell part. Chart mongers were shaking in the .50's anyway just for the reason that happened today. The pps didn't break back out of the .70's so it was a down signal. .50's with no short term jump in price probably was just the last straw for traders also. Many have stop loss points also. SOOOOOOOOOO if you consider all the reasons along with stock dilution even if for a good reason....no one should be surprised and just buy some more while you can get it lower. These are all external reasons and good for long term accumulation imho. I think the reactions get bigger as the base of investors increases An opportunity as the pps stabilizes before turning back up....sometimes days, weeks or a few months max......keep the faith(or).......comtek
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204%2D05%2D022323%2Etxt&FilePath...
More shares available......plans....strategies,financing, stuff...it is all in the link to the SEC filing.
I beleive the price is down because of the confusion and possible dilution....it is long reading ...but it seems that there is incentive for a lower price temporarily to give moire shares based on a valuation.....you tell me your take on it
I still like this conglomerate company...hard to take a share price drop on the chin....bought more today though
THE ORIGINAL GENE SILENCING COMPANY
<http://www.molecula.com/new/siRNA.html> pDsiPHERT-GFP shRNA Vector Kit
RNA interference (RNAi) is widely recognized as a powerful tool for targeted
gene silcencing. The use of commercially synthesized small interfering RNA
(siRNA) is a simple and reliable method for silencing any gene of interest.
Careful siRNA design can significantly improve siRNA potency and
specificity. MoleculA offers custom RNAi Oligo design for any mRNA target.
New to RNAi? Then visit our RNAi resource page
<http://www.molecula.com/new/newtoRNAi.html> to view animations of the RNAi
process
* Complete sequence information is always supplied upon delivery of
the order at no extra charge.
* Don't trust your RNAi experiment to a computer program. MoleculA's
lab researchers select the optimal target, while you approve the final
selection.
Custom siRNA Design
MoleculA offers custom siRNA design
<http://www.molecula.com/new/siRNA_inquiry.html> for any target mRNA.
Complete sequence information is provided with your order at no extra cost.
Easy to Order
Simply complete our RNAi oligo order form
<http://www.molecula.com/new/custom.html> , MoleculA's technical staff will
do the rest! Synthesis begins with your design approval.
>> Ultra Pure
Consistent results start with MoleculA's advanced RNA
<http://www.molecula.com/new/sirna_custom.html> chemistry and purification.
Vector-mediated RNAi
>> pDsiPHER <http://www.molecula.com/new/shRNA.html> T shRNA vectors offers
a cost-effective and easy to handle alternative to traditional,
synthetic-RNA based approaches.
Cost Effective
Create multiple designs to target your gene of interest. ONLY ORDER ONCE!
Time Saver
Let MoleculA's siRNA technology work for you (link to
<http://www.molecula.com/new/shRNA_designer.html> designer).
Transfection Reagents
iFECT <http://www.molecula.com/new/transfect.html> T, MoleculA's siRNA
transfection reagent is affordable and efficient for transfecting a wide
variety of cell types with low toxicity.
Effective Gene Knockdown
Transfect with high efficiency to study the cellular and functional
consequences of gene knockdown.
>> Exceptional Value
Choose iFECT siRNA Transfection Reagent to improve your research while
effectively silencing genes.
Order yours <http://stores.molecula.com/Detail.bok?no=50> today
W W W. M O L E C U L A. C O M
MoleculA / 22863 Bryant Court, Suite 102 / Sterling, VA 20166 / t:
800-381-0856 / f: 703-481-9209
<http://www.molecula.com/new/unsubscribe.html> unsubscribe
C Copyright 2005 moleculA. All rights reserved.
CalbaTech LifeStem Subsidiary Files for Key Patent for Its Stem Cell Delivery Device
http://www.calbatech.com/06142005.html
Agree.EOM.
Skoob,
It just keeps getting better. News bytes and stories on CYGX are getting picked up by alot of Bio-tech sites. When we break a new high with other news with this additional exposure it may give us the legs we have been looking for....stock alerts will trigger....a higher support level will move in.
Compared to 2 years ago....we have taken off already and are so close to realizing our patience.
I am starting to get excited.....I used to just be optimistic. Alot in the pipeline. Someone is going to start paying us for the future action and values early on.....Share price won't stay down I don't think through the testing levels with all that is materializing.................comtek
CalbaTech Announces Revenue Increase in First Quarter 2005; Discusses LifeStem Inc., Its Subsidiary, Focusing Exclusively on the Emerging Adult Stem Cell Market
http://www.nasdaq.com//aspxcontent/newsstory.aspx?selected=CLBE&symbol=CLBE&textpath=2005052...
Skoob,
Well noted. CYGX has been very methodical in it's methods since I have started following in 1999. They do not operate or take actions to make things look good. They just do what they need to do to get to the ultimate goal....profitability and results. We are on a good path...I echo,our time is near.....comtek
Mycom Expands mailMAXTM Channel Program Nationally
http://www.mycom.com/investor/article.php?id=28
Mycom Announces Reverse Stock Split
http://www.nasdaq.com//aspxcontent/newsstory.aspx?selected=MYCO&symbol=MYCO&textpath=2005051...
CalbaTech Files Annual Report; Projects $2.2 Million in Revenues in Reagents Division in 2005; Outlines Expectations for Stem Cell Subsidiary
http://www.nasdaq.com//aspxcontent/newsstory.aspx?selected=CLBEE&symbol=CLBEE&textpath=20050...
Mycom Adds Encryption Security to Email Service
http://www.nasdaq.com//aspxcontent/newsstory.aspx?selected=MYCO&symbol=MYCO&textpath=2005050...
Held up well today in a down mkt
Nothing like a little suspense
For TA guys; Buy confirmed CYGX today Am Bulls
http://www.americanbulls.com/StockPage.asp?CompanyTicker=CYGX&MarketTicker=OTC&TYP=S
Neo43, makes sense. Alpha L. is very well endowed, they are a possibility. I feel CYGX will get a larger cut than small though.
Paulness, very cool site...very virtual
I am awaiting it also.
I may try to get some tomorrow....sure seems like the right time. I also have some buy orders in place a few cents lower in case. If we liked it at .25.....
Welcome back Scoob.....been wait'n for you.
(Gary)............comtek
I am very curious as to how they are making these aquisitions without cash laying around. It is a good plan to have a "sum of the parts" plan to entise companies to join the ranks. They are certainly creative, you have to give them that.
Notification of late filing 10-KSB
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001094328%2D05%2D000074%2Etxt&FilePath....
"
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last year will be reflected by the earnings statement to be included in the subject report or portion thereof?
[ ] Yes [ X ] No
"
NT 10K was filed on 3-31 for 2003 and 2004. Hopefully this doesn't mean anything. They should have something this week. 4-1 was on Friday. I expect to see particulars of the last deals made. I don't blame you for laying low until there is some visibilty.
Mycom adds mailMAX contracts with Banks and Insurance Groups
http://www.nasdaq.com/asp/quotes_news.asp?selected=MYCO&symbol=MYCO&textpath=20050401%5CACQB....
Mycom reports 2004 performance
http://www.nasdaq.com/asp/quotes_news.asp?selected=MYCO&symbol=MYCO&textpath=20050330%5CACQB....
Oops! Error, I hit the wrong bookmark, posted and moved on. I never go OT(until now).
I did buy some CLBE this week though.....best,....comtek.
Mycom adds mailMAX contracts with Banks and Insurance Groups
http://www.nasdaq.com/asp/quotes_news.asp?selected=MYCO&symbol=MYCO&textpath=20050401%5CACQB...
A good hold and this is typical of this kind of situation. It will just pop with news and go down without it. Once we get some income data, things will firm up. Hold tight, accumulate on dips. The spread makes it tough to trade. Moves alot on little to no volume.
Incite, best point-radio show is that by obtaining income producing companies dilution will be minimized. Statement of undervaluation of this stock as compared to peers......and we'll be watching, waiting and accumulating
Spam Costs World Businesses $50 Billion
By Gregg Keizer, TechWeb News
2:39 PM EST Wed. Feb. 23, 2005
Spam will cost the world $50 billion in lost productivity and other expenses a research firm said Wednesday, with more than a third of that -- $17 billion -- wasted by U.S. firms.
According to San Francisco-based Ferris Research's newest report, spam's cost is primarily in lost worker time as employees filter spam, deal with false positives, and query corporate help desks for assistance with the plague.
"But the costs could be a lot worse," said Richi Jennings, one of the Ferris analysts who authored the report. "We haven't seen as much of a spike in costs as in spam volume," he added, "because more organizations are putting in better anti-spam technology."
Since 2003, for example, spam volume hitting U.S. enterprises has jumped five fold, while costs have not even doubled. In 2003, Ferris estimated spam costs to U.S. organizations at $10 billion, with 2005's lost money amounting to $17 billion.
With such great sums of money at stake -- 0.17 percent of the U.S. gross national income -- it's easy for companies to make a business case for anti-spam technology, particularly in developed countries where labor costs are higher (thus raising the dollars lost to productivity drains) and spam volumes larger.
"For developed countries, deploying competent spam filtering software makes good business sense," said Jennings. "The business case in emerging economies is less clear-cut."
In countries such as India and China, where spam volumes are relatively low (so far) and labor costs are rock-bottom, costs are less than a third of those in the U.S. per mailbox. "If all you're considering is the direct measurable cost and nothing else, you could say that part of these people's jobs is to delete spam," said Jennings. "It's simply because labor is so much cheaper."
But in higher-priced economies -- such as the U.S., Europe, and Japan -- costs skyrocket, and vary to a surprising degree.
In the U.S., for instance, spam's annual per-mailbox cost to businesses is $170. In Germany, however, that number jumps to $241 a year. Germany's labor costs are higher, noted Jennings, because of fewer work days and high health care and pension costs borne by businesses.
Nor is every method of filtering spam equal in economy, he added. Server-based filtering is considerably cheaper than desktop-based anti-spam solutions: the former typically costs $132 per year per user, while the latter runs $217.
Doing nothing costs even more, since manually filtering drives up the spam price tag to a whopping $718 per year per user.
"There are very few scenarios where we would recommend desktop filtering," said Jennings, "unless it was a 'belt and braces' approach with multiple layers at, say, the gateway, inside the network, and on the desktop. But I don't see any trend of this."
It's hard to make a financial case for desktop filtering, he added, since the IT management costs are so much greater for that tactic compared to filtering at the server. "Anytime an IT department has to roll out software to everyone's desktop, you're talking serious money," he said. Sometimes people try to make the case that desktop-only filtering is more economical for small companies or for those organizations where a minority of the workers receive most of the spam, but "even then, a hosted spam filtering service from a third-party service provider will probably be more economical and effective," Jennings said.
It appears someone got a large share block on the 22nd, up to 900k, missed the actual trades but there were not many at the time I had looked and the volume was up there.
Molecula remains focused on gene silencing techniques using synthetic RNAi oligos
Molecula's AntistrandT eNewsletter
February 2005
Molecula remains focused on gene silencing techniques using synthetic RNAi oligos, pre-designed RNAi to many targets and new pDsiPHERT shRNA vectors. Molecula continues to provide its customers with superior designed sequences for all RNAi and antisense products. Molecula also offers superior molecular biology reagents such as transfection reagents, IPTG, and numerous other products. Visit our website to see what we have to offer.
www.molecula.com
New pDsiPHERT shRNA Vectors!
pDsiPHERT shRNA vectors express a short hairpin RNA (shRNA) of approximately 59-61 nucleotides in length from a polIII promoter. Inside the cell, the shRNAs are processed into 19 nt siRNAs, causing gene silencing in the same way as siRNAs that are produced synthetically. Vector-mediated RNA interference offers a cost-effective, easy to handle alternative to traditional, synthetic-RNA based approaches.
More Info On pDsiPHERT Vectors
Transfection Reagents
iFECTT, MaxfectT and GenfectT transfection reagents meet all your transfection needs:
a.. iFECTT for transfection of synthetic siRNAs
b.. MaxfectT for traditional transfection requirements
c.. GenfectT for those difficult to transfect cell lines
More About Transfection Reagents
Biochemicals
IPTG, 5g - $39
IPTG, 100g - $429
X-Gal, 1g - $49
Complete List of Biochemicals and Reagents
RNAi and Antisense
Pre-designed RNAi, custom RNAi synthesis, custom antisense oligo synthesis and design.
RNAi
Antisense Oligos
MoleculA / 22863 Bryant Court, Suite 102 / Sterling, VA 20166
t: 800-381-0856 / f: 703-481-9209 / www.molecula.com
2-15 Mycom Partners With PGP Corporation to Add Encryption to Email Services
http://www.nasdaq.com/asp/quotes_news.asp?cpath=20050215\ACQBIZ200502150923BIZWIRE_USPR_____BW5650.h...
Anti-virus software provider Sybari Software sets IPO terms
Sybari Software (SYBS)
Offers anti-virus and anti-spam software to 10,000 enterprises and government agencies.
Sybari Software, which offers anti-virus and anti-spam software to 9,000 enterprises and government agencies, released its IPO terms in an SEC filing on Thursday. The company plans to offer 3.4 million shares with a price range of $14 to $16, resulting in an estimated market cap of $175 million. SG Cowen is the lead underwriter on the deal. The company has filed to be traded on the NASDAQ under the ticker SYBS
IPO Profile
Expected Date Week of 2/7/05
IPO File Date 5/14/04
Price Range $14.00 - $16.00
Shares Offered 3.4 mm
http://www.ipohome.com/marketwatch/iponews2.asp?article=4188
If Mycom can get it going hopefully our PPS will start to gravitate toward our peers
Discussion about genetics in agriculture would be interesting while waiting for CYGX to explode. Check out ICOR(Icoria), they have some great products and an intersting approach.
Quote from this month's MIT's Technology Reveiw....
"There is no better way to get a feel for the future of emerging technologies than by looking at what is getting funding-and what isn't. Though the private and public markets are once again bullish on certain technologies, federal funding for non-defense R&D is in decline, and that has many worried. A team of Technology Reveiw editors finds hope, but also danger, for tech financing."
A great magazine if you like that type of thing....
This month's cover(March)not on site yet...."TECH+FINANCE 2005"
also at
http://www.technologyreview.com/
Covers everything from the FDA to the newest in emerging technologies....alot of genetic, robotic and nano-tech coverage. There is a lot of great information to give some insight to the acceptance of technologies like CYGX is developing.
CLBE is also putting together a basket of companies that have some great potential if funding swings toward bio-tech. It is interesting to see who gets grants and why and how it applies to CYGX efforts.
CYGX is still a stand alone company, I personally hope we can make all the way without being bought. It is worth the wait IMHO.
Neo....Your OT post is so refreshing on the board gone astray. I never thought I would enjoy an OT post here. I hope this board will return to the comradery and intellectual posts of a year ago soon.....comtek
Thanks. Quote from this month's MIT's Technology Reveiw....
"There is no better way to get a feel for the future of emerging technologies than by looking at what is getting funding-and what isn't. Though the private and public markets are once again bullish on certain technologies, federal funding for non-defense R&D is in decline, and that has many worried. A team of Technology Reveiw editors finds hope, but also danger, for tech financing."
A great magazine if you like that type of thing....
This month's cover(March)not on site yet...."TECH+FINANCE 2005"
also at
http://www.technologyreview.com/
Covers everything from the FDA to the newest in emerging technologies....alot of genetic, robotic and nano-tech coverage.
CLBE seems to be heading to the right place at the right time. It is putting together a great basket of companies in the reagents and consumables dept. iStem is just one part of our opportunity as you well know. I think funding opportunities will converge at some point with CLBE whether we need them or not. Awareness and acceptability is evolving quickly if one looks at the timetable this is all occurring in the stem cell arena. It is great that iStem is working on delivery methods.
Stem cell committee expects to award first grants in May
LOS ANGELES (AP) — The California Institute for Regenerative Medicine doesn't have a home, any money, or even a single employee, but the head of the new state agency expects to be awarding its first grants for stem cell research by May.
"We have a responsibility to move as quickly as possible," Robert Klein said Thursday. "I admit that I am an optimist."
http://www.usatoday.com/news/health/2005-01-07-stem-cell_x.htm